Literature DB >> 11015454

Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology.

K M Mattila1, J O Rinne, M Röyttä, P Laippala, T Pietilä, H Kalimo, T Koivula, H Frey, T Lehtimäki.   

Abstract

Alzheimer's disease (AD) and Parkinson's disease (PD) are genetically heterogeneous. Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) genes may modify the risk of these disorders. We investigated whether common polymorphisms present in these genes operate as risk factors for AD and PD in Finnish subjects, independently or in concert with the apolipoprotein E epsilon4 allele (APOE epsilon4). Eighty late onset sporadic AD patients, 53 PD patients (34 of whom had concomitant AD pathology), and 67 control subjects were genotyped for the insertion (I)/deletion (D) polymorphism of DCP1 and the K variant of BCHE. In logistic regression analysis, the DCP1 *I allele in combination with APOE epsilon4 significantly increased the risk of AD (OR 30.0, 95% CI 7.3-123.7), compared to subjects carrying neither of the alleles. Similar analysis showed that the risk of AD was significantly increased in subjects carrying both the BCHE wild type (*WT/*WT) genotype and epsilon4 (OR 9.9, 95% CI 2.9-33.8), compared to those without this BCHE genotype and epsilon4. Further, the risk of PD with AD pathology was significantly increased for carriers of DCP1 *I and epsilon4 (OR 8.0, 95% CI 2.1-31.1). We thus conclude that, in Finns, interaction between DCP1 *I and epsilon4 increases the risk of AD as well as of PD with coexisting Alzheimer pathology, which underlines the importance of the DCP1 I/D polymorphism in the development of Alzheimer neuropathology, whereas the wild type BCHE genotype in combination with epsilon4 had a combined effect with regard to the risk of AD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11015454      PMCID: PMC1757160          DOI: 10.1136/jmg.37.10.766

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  35 in total

1.  Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer's disease patients.

Authors:  M Hiltunen; A Mannermaa; S Helisalmi; A Koivisto; M Lehtovirta; M Ryynänen; P Riekkinen; H Soininen
Journal:  Neurosci Lett       Date:  1998-06-26       Impact factor: 3.046

2.  Butyrylcholinesterase K: an association with dementia with Lewy bodies.

Authors:  A B Singleton; A M Gibson; J A Edwardson; I G McKeith; C M Morris
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

3.  The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease.

Authors:  P G Kehoe; H Williams; P Holmans; G Wilcock; N J Cairns; J Neal; M J Owen
Journal:  J Med Genet       Date:  1998-12       Impact factor: 6.318

4.  Apolipoprotein E epsilon4 allele frequency is increased in Parkinson's disease only with co-existing Alzheimer pathology.

Authors:  P M Mattila; T Koskela; M Röyttä; T Lehtimäki; T A Pirttilä; E Ilveskoski; P Karhunen; J O Rinne
Journal:  Acta Neuropathol       Date:  1998-10       Impact factor: 17.088

5.  The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations.

Authors:  F Crawford; D Fallin; Z Suo; L Abdullah; M Gold; A Gauntlett; R Duara; M Mullan
Journal:  Neurosci Lett       Date:  1998-06-19       Impact factor: 3.046

Review 6.  Genetic polymorphisms in Parkinson's disease.

Authors:  H Checkoway; F M Farin; P Costa-Mallen; S C Kirchner; L G Costa
Journal:  Neurotoxicology       Date:  1998 Aug-Oct       Impact factor: 4.294

Review 7.  Molecular genetics of Alzheimer's disease.

Authors:  M Cruts; C Van Broeckhoven
Journal:  Ann Med       Date:  1998-12       Impact factor: 4.709

Review 8.  The genetics of Parkinson's disease and parkinsonian syndromes.

Authors:  N P Bajaj; C Shaw; T Warner; K RayChaudhuri
Journal:  J Neurol       Date:  1998-10       Impact factor: 4.849

9.  ACE, MTHFR, factor V Leiden, and APOE polymorphisms in patients with vascular and Alzheimer's dementia.

Authors:  J Chapman; N Wang; T A Treves; A D Korczyn; N M Bornstein
Journal:  Stroke       Date:  1998-07       Impact factor: 7.914

10.  Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease.

Authors:  P G Kehoe; C Russ; S McIlory; H Williams; P Holmans; C Holmes; D Liolitsa; D Vahidassr; J Powell; B McGleenon; M Liddell; R Plomin; K Dynan; N Williams; J Neal; N J Cairns; G Wilcock; P Passmore; S Lovestone; J Williams; M J Owen
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

View more
  13 in total

Review 1.  Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.

Authors:  Gohar Mushtaq; Nigel H Greig; Jalaluddin A Khan; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

2.  Association of BDNF and BCHE with Alzheimer's disease: Meta-analysis based on 56 genetic case-control studies of 12,563 cases and 12,622 controls.

Authors:  Huihui Ji; Dongjun Dai; Yunliang Wang; Danjie Jiang; Xingyu Zhou; Peipei Lin; Xiaosui Ji; Jinfeng Li; Yuzheng Zhang; Honglei Yin; Rongrong Chen; Lina Zhang; Mingqing Xu; Shiwei Duan; Qinwen Wang
Journal:  Exp Ther Med       Date:  2015-03-03       Impact factor: 2.447

3.  An association analysis of Alzheimer disease candidate genes detects an ancestral risk haplotype clade in ACE and putative multilocus association between ACE, A2M, and LRRTM3.

Authors:  Todd L Edwards; Margaret Pericak-Vance; Johnny R Gilbert; Jonathan L Haines; Eden R Martin; Marylyn D Ritchie
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-07-05       Impact factor: 3.568

4.  A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Authors:  Agneta Nordberg; Clive Ballard; Roger Bullock; Taher Darreh-Shori; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-07

5.  A multi-center study of ACE and the risk of late-onset Alzheimer's disease.

Authors:  Olivia Belbin; Kristelle Brown; Hui Shi; Christopher Medway; Richard Abraham; Peter Passmore; David Mann; A David Smith; Clive Holmes; Bernadette McGuinness; David Craig; Donald Warden; Reinhard Heun; Heike Kölsch; Seth Love; Noor Kalsheker; Julie Williams; Michael J Owen; Minerva Carrasquillo; Steven Younkin; Kevin Morgan; Patrick G Kehoe
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 6.  Mechanisms of neuronal death in disease: defining the models and the players.

Authors:  Elena M Ribe; Esther Serrano-Saiz; Nsikan Akpan; Carol M Troy
Journal:  Biochem J       Date:  2008-10-15       Impact factor: 3.766

7.  Genotator: a disease-agnostic tool for genetic annotation of disease.

Authors:  Dennis P Wall; Rimma Pivovarov; Mark Tong; Jae-Yoon Jung; Vincent A Fusaro; Todd F DeLuca; Peter J Tonellato
Journal:  BMC Med Genomics       Date:  2010-10-29       Impact factor: 3.063

8.  Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection?

Authors:  Gumpeny Ramachandra Sridhar; Hanuman Thota; Appa Rao Allam; Changalasetty Suresh Babu; Akula Siva Prasad; Ch Divakar
Journal:  Lipids Health Dis       Date:  2006-11-11       Impact factor: 3.876

9.  Butyrylcholinesterase K variant and Alzheimer's disease risk: a meta-analysis.

Authors:  Zongcheng Wang; Yuren Jiang; Xi Wang; Yangsen Du; Dandan Xiao; Youchao Deng; Jinlian Wang
Journal:  Med Sci Monit       Date:  2015-05-16

10.  Angiotensin-converting enzyme insertion/deletion polymorphism is not a major determining factor in the development of sporadic Alzheimer disease: evidence from an updated meta-analysis.

Authors:  Xue-bin Wang; Ning-hua Cui; Jie Yang; Xue-ping Qiu; Jia-jia Gao; Na Yang; Fang Zheng
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.